Hepatitis C virus Envelope glycoprotein fitness defines virus population composition following transmission to a new host

Journal of Virology

Volumn 86, Issue 22, 2012, Pages 11956-11966

  Brown, Richard J P ^a,b,i   Hudson, Natalia ^a,b   Wilson, Garrick ^c   Rehman, Shafiq Ur ^a,b   Jabbari, Sara ^a   Hu, Ke ^c   Tarr, Alexander W ^a,b   Borrow, Persephone ^d   Joyce, Michael ^e   Lewis, Jamie ^e   Zhu, Lin Fu ^f   Law, Mansun ^g   Kneteman, Norman ^e,f,h   Lorne Tyrrell, D ^e,h   McKeating, Jane A ^c   Ball, Jonathan K ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g SCRIPPS RESEARCH INSTITUTE   (United States)

^h KMT Hepatech Inc   (Canada)

ⁱ INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAYES THEOREM; CHIMERA; CONTROLLED STUDY; E1E2 GENE; EXPERIMENTAL MOUSE; GENE; GENE AMPLIFICATION; GENE FUNCTION; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; GLYCOSYLATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INOCULATION; LIVER CELL; MATHEMATICAL MODEL; MICROBIAL POPULATION DYNAMICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; SINGLE GENOME AMPLIFICATION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS PARTICLE; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ANIMALS; BAYES THEOREM; CELL TRANSPLANTATION; EPITOPES; FOUNDER EFFECT; GENETIC VARIATION; GENOME; GLYCOPROTEINS; HEPATITIS C; HEPATOCYTES; HUMANS; MICE; MICE, SCID; MODELS, THEORETICAL; PEPTIDES; PHENOTYPE; SPECIES SPECIFICITY; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VIRAL ENVELOPE PROTEINS;

HEPATITIS C VIRUS; MUS; RNA VIRUSES;

EID: 84869143643     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01079-12     Document Type: Article

References (68)

1. Alter MJ. 2002. Prevention of spread of hepatitis C. Hepatology 36:S93-98.
2. Anderson JA, et al. 2010. HIV-1 populations in semen arise through multiple mechanisms. PLoS Pathog. 6:e1001053. doi:10.1371/journal.ppat.1001053.
3. Bar KJ, et al. 2009. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J. Virol. 84:6241-6247.
4. Brown RJ, et al. 2011. Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors. J. Virol. 85:6024-6037.
5. Brown RJP, et al. 2007. Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes. J. Gen. Virol. 88:458-469.
6. Buchbinder SP, et al. 1994. Hepatitis C virus infection in sexually active homosexual men. J. Infect. 29:263-269.
7. Bukh J, Miller RH, Purcell RH. 1995. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 15:41-63.
8. Bull RA, et al. 2011. Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog. 7:e1002243. doi:10.1371/journal.ppat.1002243.
9. Cavalheiro NP, De La Rosa A, Elagin S, Tengan FM, Araújo ES, Barone AA. 2009. Hepatitis C: sexual or intrafamilial transmission? Epidemiological and phylogenetic analysis of hepatitis C virus in 24 infected couples. Rev. Soc. Bras. Med. Trop. 42:239-244.
10. Ciesek S, et al. 2010. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 138:1875-1884.
11. Ciesek S, Wedemeyer H. 2012. Immunosuppression, liver injury and post-transplant HCV recurrence. J. Viral Hepat. 19:1-8.
12. Curran R, et al. 2002. Evolutionary trends of the first hypervariable region of the hepatitisCvirus E2 protein in individuals with differing liver disease severity. J. Gen. Virol. 83:11-23.
13. Dahari H, et al. 2005. Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology 128:1056-1066.
14. Derdeyn CA, et al. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303:2019-2022.
15. Dorner M, et al. 2011. A genetically humanized mouse model for hepatitisC virus infection. Nature 474:208-211.
16. Drummer HE, Boo I, Maerz AL, Poumbourios P. 2006. A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J. Virol.80:7844-7853.
17. Drummer HE, Poumbourios P. 2004. Hepatitis C virus glycoprotein E2 contains a membrane-proximal heptad repeat sequence that is essential for E1E2 glycoprotein heterodimerization and viral entry. J. Biol. Chem.279:30066-30072.
18. Drummond A, Ho S, Phillips M, Rambaut A. 2006. Relaxed phylogenetics and dating with confidence. PLoS Biol. 4:e88. doi:10.1371/journal.pbio.0040088.
19. Drummond AJ, Rambaut A. 2007. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol. Biol. 7:214.
20. Fafi-Kremer S, et al. 2010. Viral entry and escape from antibodymediated neutralization influence hepatitis C virus reinfection in liver transplantation. J. Exp. Med. 207:2019-2031.
21. Goffard A, et al. 2005. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol. 79:8400-8409.
22. Goldberg D, Anderson E. 2004. Hepatitis C: who is at risk and how do we identify them? J. Viral Hepat. 11:12-18.
23. Helle F, et al. 2007. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J.Virol. 81:8101-8111.
24. Helle F, et al. 2010. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J. Virol.84:11905-11915.
25. Hsu M, et al. 2003. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. U. S. A.100:7271-7276.
26. Johansson DX, et al. 2007. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 104:16269-16274.
27. Keck ZY, et al. 2004. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J. Virol. 78:9224-9232.
28. Keele BF, et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl.Acad. Sci. U. S. A. 105:7552-7557.
29. Kneteman NM, Toso C. 2009. In vivo study of HCV in mice with chimeric human livers. Methods Mol. Biol. 510:383-399.
30. Kumar U, Brown J, Monjardino J, Thomas HC. 1993. Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection. J. Infect. Dis. 167:726-730.
31. Lavillette D, et al. 2005. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41:265-274.
32. Law M, et al. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14:25-27.
33. Li H, et al. 2010. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog. 6:e1000890. doi:10.1371/journal.ppat.1000890.
34. Lin HJ, Seeff LB, Barbosa L, Hollinger FB. 2001. Occurrence of identical hypervariable region 1 sequences of hepatitis C virus in transfusion recipients and their respective blood donors: divergence over time. Hepatology 34:424-429.
35. Liu W, et al. 2010. Origin of the human malaria parasite Plasmodium falciparum in gorillas. Nature 467:420-425.
36. Manzin A, et al. 2000. Dominant role of host selective pressure in driving hepatitis C virus evolution in perinatal infection. J. Virol. 74:4327-4334.
37. Manzin A, et al. 1998. Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J. Virol. 72:6271-6276.
38. McAllister J, et al. 1998. Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort. J. Virol. 72:4893-4905.
39. McCaffrey AP, et al. 2002. Determinants of hepatitis C translational initiation in vitro, in cultured cells and mice. Mol. Ther. 5:676-684.
40. Mee CJ, et al. 2010. Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Gastroenterology 138:1134-1142.
41. Mercer DF, et al. 2001. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7:927-933.
42. Meuleman P, Leroux-Roels G. 2008. The human liver-uPA-SCID mouse:a model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Res. 80:231-238.
43. Meunier J-C, et al. 2008. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus. J. Virol. 82:966-973.
44. Miller FD, Abu-Raddad LJ. 2010. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc. Natl. Acad. Sci. U. S. A.107:14757-14762.
45. Mitry RR. 2009. Isolation of human hepatocytes. Methods Mol. Biol.481:17-23.
46. Mizuno Y, et al. 1997. Study of needlestick accidents and hepatitis C virus infection in healthcare workers by molecular evolutionary analysis. J.Hosp. Infect. 35:149-154.
47. Neumann AU, et al. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107.
48. Owsianka A, et al. 2005. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J.Virol. 79:11095-11104.
49. Owsianka AM, et al. 2008. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol. 89:653-659.
50. Owsianka AM, et al. 2006. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81binding. J. Virol. 80:8695-8704.
51. Perelson AS. 2002. Modelling viral and immune system dynamics. Nat. Rev. Immunol. 2:28-36.
52. Perotti M, et al. 2008. Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J. Virol. 82:1047-1052.
53. Posada D, Crandall KA. 1998. MODELTEST: testing the model of DNA substitution. Bioinformatics 14:817-818.
54. Ray SC, et al. 2000. Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees. J. Virol. 74:3058-3066.
55. Sabo MC, et al. 2011. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J. Virol. 85:7005-7019.
56. Salazar-Gonzalez JF, et al. 2008. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by singlegenome amplification and sequencing. J. Virol. 82:3952-3970.
57. Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R. 2011. HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog. 7:e1002286. doi:10.1371/journal.ppat.1002286.
58. Shapiro B, Rambaut A, Drummond AJ. 2006. Choosing appropriate substitution models for the phylogenetic analysis of protein-coding sequences.Mol. Biol. Evol. 23:7-9.
59. Simmonds P. 2004. Genetic diversity and evolution of hepatitis C virus-15 years on. J. Gen. Virol. 85:3173-3188.
60. Sugitani M, Shikata T. 1998. Comparison of amino acid sequences in hypervariable region-1 of hepatitis C virus clones between human inocula and the infected chimpanzee sera. Virus Res. 56:177-182.
61. Swofford DL. 1998. PAUP*: Phylogenetic Analysis Using Parsimony (*and other methods). Sinauer Associates, Sunderland, MA.
62. Tamura K, Nei DJM, Kumar S. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24:1596-1599.
63. Tarr AW, et al. 2006. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 43:592-601.
64. Thomson PC, et al. 2011. A case of hepatitis C virus transmission acquired through sharing a haemodialysis machine. Nephrol. Dial. Transplant. Plus 4:33-35.
65. Tong MJ, El-Farra NS, Reikes AR, Co RL. 1995. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 332:1463-1466.
66. Villano AS, Vlahov D, Nelson EK, Cohn S, Thomas LD. 1999. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29:908-914.
67. Wang GP, Sherrill-Mix SA, Chang K-M, Quince C, Bushman FD. 2010. HepatitisCvirus transmission bottlenecks analyzed by deep sequencing. J.Virol. 84:6218-6228.
68. Weiner AJ, et al. 1993. A unique, predominant hepatitis C virus variant found in an infant born to a mother with multiple variants. J. Virol. 67:4365-4368.